share_log

Affimed Analyst Ratings

アッフィメドのアナリスト評価

Benzinga ·  2023/09/25 10:08
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/25/2023 1417.45% Cantor Fitzgerald → $7 Reiterates Overweight → Overweight
09/12/2023 1417.45% Cantor Fitzgerald → $7 Reiterates Overweight → Overweight
09/07/2023 1417.45% Cantor Fitzgerald → $7 Reiterates Overweight → Overweight
08/11/2023 1200.67% Truist Securities $8 → $6 Maintains Buy
08/11/2023 983.89% HC Wainwright & Co. → $5 Reiterates Buy → Buy
08/08/2023 1200.67% Berenberg → $6 Assumes → Buy
06/05/2023 983.89% HC Wainwright & Co. $6 → $5 Maintains Buy
05/24/2023 1200.67% HC Wainwright & Co. → $6 Reiterates Buy → Buy
03/27/2023 1417.45% Wells Fargo → $7 Assumes → Overweight
03/24/2023 116.78% Stifel $2 → $1 Maintains Hold
03/24/2023 1200.67% HC Wainwright & Co. → $6 Reiterates → Buy
12/12/2022 1417.45% Wells Fargo $8 → $7 Maintains Overweight
12/12/2022 1200.67% Piper Sandler $7 → $6 Maintains Overweight
12/12/2022 1200.67% SVB Leerink $10 → $6 Maintains Outperform
12/12/2022 1200.67% HC Wainwright & Co. → $6 Initiates Coverage On → Buy
10/10/2022 333.56% Stifel $9 → $2 Downgrades Buy → Hold
06/23/2022 1851.01% SVB Leerink $10 → $9 Maintains Outperform
03/31/2022 1417.45% Piper Sandler → $7 Initiates Coverage On → Overweight
02/23/2022 2501.34% Cantor Fitzgerald → $12 Initiates Coverage On → Overweight
10/21/2021 2067.79% Truist Securities → $10 Initiates Coverage On → Buy
10/12/2021 2501.34% SVB Leerink $13 → $12 Maintains Outperform
09/30/2021 2501.34% Stifel → $12 Initiates Coverage On → Buy
03/31/2021 3151.68% Credit Suisse → $15 Initiates Coverage On → Outperform
03/24/2021 3151.68% Wells Fargo $10 → $15 Maintains Overweight
03/11/2021 2934.9% SVB Leerink $9 → $14 Maintains Outperform
11/11/2020 1851.01% SVB Leerink $8 → $9 Maintains Outperform
06/24/2020 1634.23% SVB Leerink $7 → $8 Maintains Outperform
03/28/2019 1634.23% SVB Leerink → $8 Initiates Coverage On → Outperform

What is the target price for Affimed (AFMD)?

The latest price target for Affimed (NASDAQ: AFMD) was reported by Cantor Fitzgerald on September 25, 2023. The analyst firm set a price target for $7.00 expecting AFMD to rise to within 12 months (a possible 1417.45% upside). 16 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Affimed (AFMD)?

The latest analyst rating for Affimed (NASDAQ: AFMD) was provided by Cantor Fitzgerald, and Affimed reiterated their overweight rating.

When is the next analyst rating going to be posted or updated for Affimed (AFMD)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Affimed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Affimed was filed on September 25, 2023 so you should expect the next rating to be made available sometime around September 25, 2024.

Is the Analyst Rating Affimed (AFMD) correct?

While ratings are subjective and will change, the latest Affimed (AFMD) rating was a reiterated with a price target of $0.00 to $7.00. The current price Affimed (AFMD) is trading at is $0.46, which is within the analyst's predicted range.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする